Faruqi & Faruqi, LLP Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Seek Counsel Before the September 28, 2026 Lead Plaintiff Deadline in the Securities Class Action

Capricor Therapeutics faces a federal securities class action alleging it misled investors over unapproved changes to Deramiocel's clinical statistical analysis plan and the resulting risk to FDA approval for Duchenne muscular dystrophy. Following the alleged corrective disclosures, Capricor shares fell approximately 64% on July 27, 2026. Investors who acquired CAPR shares from December 17, 2025 through July 26, 2026 have until September 28, 2026 to seek lead-plaintiff status.

Analysis

The litigation notice is not independent evidence of misconduct, but it crystallizes the market's core issue: regulatory credibility rather than a routine clinical-data debate. If FDA determines that post hoc analysis changes undermine the evidentiary standard, CAPR faces a binary shift from a near-term commercial-asset valuation toward a cash-runway valuation; the relevant downside is therefore determined by quarterly cash burn, not the size of any eventual legal settlement. The class action itself is unlikely to be a meaningful direct financial liability relative to the approval-risk repricing.

Over the next days to three months, CAPR should remain highly sensitive to any FDA filing-status clarification, Complete Response Letter, advisory-committee decision, or management disclosure on whether the agency accepted the revised analysis. A delayed or failed BLA outcome would also raise dilution risk because a smaller-cap biotech with a single pivotal regulatory catalyst typically loses financing leverage precisely when incremental trials or data-generation may be required. Conversely, a clear FDA statement that the analysis is acceptable would force a sharp short-covering rally after the 64% corrective move, making outright short exposure unattractive without a defined catalyst.

The second-order beneficiary is SRPT only at the margin: a setback for an alternative Duchenne therapy reinforces the scarcity value of commercially established treatment franchises, but CAPR's asset-specific statistical issue does not alter SRPT's own safety, label, or reimbursement risks. Consensus may overread the lawsuit as new information; the actionable signal is not the filing deadline, but whether CAPR can demonstrate prospective FDA alignment and preserve enough cash to bridge any regulatory delay.

Key Decisions for Investors

• Do not initiate a fresh directional CAPR short solely on this notice. The post-correction setup is binary and vulnerable to a regulatory-process clarification; reassess only after FDA communication or the next earnings release discloses cash runway, BLA status, and expected decision timing.
• For existing CAPR longs, reduce exposure unless the position is explicitly sized as a regulatory-optionality investment. A thesis is falsified by confirmation that FDA did not endorse the revised analysis or by guidance implying a new pivotal study; retain only a small position sized for a potential approval-related rebound.
• Set event alerts for: FDA acceptance/refusal of the analytical approach, any PDUFA or CRL disclosure, quarterly net cash use, and an at-the-market/equity financing announcement. A financing before regulatory clarity would signal impaired negotiating power and likely extend downside beyond the initial reaction.
• Use SRPT as a relative watch item rather than a direct pair trade. Consider incremental long exposure only if CAPR's setback is accompanied by improving SRPT-specific reimbursement, demand, or safety data; CAPR's regulatory dispute alone is insufficient to support a durable SRPT re-rating.